Regencell Bioscience Ltd., trading on the NASDAQ under the symbol RGC, is a clinical‐stage biotechnology company focused on developing innovative immunotherapies and vaccines. Established in 2004 as a spin‐off from academic research in Israel, the company has built a portfolio that combines personalized cell‐based cancer treatments with next‐generation vaccines for infectious diseases. Regencell’s core mission is to harness the body’s immune system to target hard‐to‐treat cancers and emerging pathogens.
The company’s pipeline features dendritic cell vaccines tailored to individual patients’ tumor profiles, designed to stimulate a potent anti‐tumor immune response. In parallel, Regencell is advancing prophylactic and therapeutic vaccines against viral threats, leveraging proprietary antigen‐delivery platforms. Its lead oncology candidates are currently in early‐phase clinical trials for solid tumors such as melanoma and colorectal cancer, while its infectious disease programs address indications including malaria and influenza.
Headquartered in Ness Ziona, Israel, Regencell operates research and manufacturing facilities that comply with international cGMP standards. The company collaborates with academic centers in North America, Europe and Asia to conduct multi‐site clinical trials and to support technology transfers. These partnerships aim to accelerate development timelines and expand access to Regencell’s therapies in global markets.
Regencell’s leadership team is led by President and Chief Executive Officer Dr. Mordechai Vardi, who brings over two decades of experience in immuno‐oncology, and Chief Scientific Officer Dr. Yitzhak Keinan, a veteran researcher in cellular vaccine design. Together with a board of directors drawn from life science venture capital and pharmaceutical development, they guide the company’s strategic direction toward regulatory milestones and eventual commercialization.
AI Generated. May Contain Errors.
